Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 401

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial

Grey, Andrew, Bolland, Mark, Gamble, Greg, Wattie, Diana, Horne, Anne, Davidson, James, Reid, Ian R.·2007·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2006-2646
Open this paper in CoChat — free account

Abstract

CONTEXT: Thiazolidinediones, which are peroxisome proliferator-activated receptor-gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor-gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies. OBJECTIVE: The objective of the study was to determine whether rosiglitazone, a thiazolidinedione, inhibits bone formation. DESIGN: The study was a 14-wk randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted in the general community. PATIENTS: Fifty healthy, postmenopausal women participated in the study. INTERVENTION: Intervention was rosiglitazone 8 mg/d. MAIN OUTCOME MEASURES: The primary end point was biochemical markers of bone formation, and secondary end points were a bone resorption marker and bone mineral density. RESULTS: The osteoblast markers procollagen type I N-terminal propeptide and osteocalcin declined by 13% (P<0.005 vs. placebo) and 10% (P=0.04 vs. placebo), respectively, in the rosiglitazone group. These changes were evident by 4 wk and persisted for the duration of the study. There was no change in the serum beta-C-terminal telopeptide of type I collagen, a marker of bone resorption (P=0.9 vs. placebo). Total hip bone density fell in the rosiglitazone group (mean change from baseline rosiglitazone -1.9%, placebo -0.2%; between-group difference 1.7%, 95% confidence interval 0.6-2.7, P<0.01); lumbar spine bone density fell significantly from baseline values in the rosiglitazone group (P=0.02 vs. baseline) but was not significantly different between groups (mean change from baseline rosiglitazone -1.2%, placebo -0.2%; between-group difference 1.0%, 95% confidence interval -0.2-2.3, P=0.13). CONCLUSIONS: Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2006-2646

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 41

  1. Kendall, 2006, Thiazolidinediones: the case for early use., Diabetes Care, 29, 154, 10.2337/diacare.29.01.06.dc05-0711 · DOI
  2. Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial., Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 · DOI · Paper page
  3. Yki-Jarvinen, 2005, The PROactive study: some answers, many questions., Lancet, 366, 1241, 10.1016/S0140-6736(05)67504-6 · DOI
  4. Gimble, 1996, Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells., Mol Pharmacol, 50, 1087
  5. Lecka-Czernik, 1999, Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2., J Cell Biochem, 74, 357, 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7 · DOI · Paper page
  6. Kawaguchi, 2005, Distinct effects of PPARγ insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells., J Bone Miner Metab, 23, 275, 10.1007/s00774-005-0599-2 · DOI
  7. Khan, 2003, Activation of peroxisome proliferator-activated receptor-γ inhibits differentiation of preosteoblasts., J Lab Clin Med, 142, 29, 10.1016/S0022-2143(03)00058-1 · DOI
  8. Okazaki, 1999, Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro., Endocrinology, 140, 5060, 10.1210/endo.140.11.7116 · DOI
  9. Mbalaviele, 2000, Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation., J Biol Chem, 275, 14388, 10.1074/jbc.275.19.14388 · DOI
  10. Akune, 2004, PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors., J Clin Invest, 113, 846, 10.1172/JCI200419900 · DOI
  11. Pei, 2004, Fat’s loss is bone’s gain., J Clin Invest, 113, 805, 10.1172/JCI21311 · doi:10.1172/jci21311 · Paper page
  12. Soroceanu, 2004, Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis., J Endocrinol, 183, 203, 10.1677/joe.1.05723 · DOI · Paper page
  13. Ali, 2005, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation., Endocrinology, 146, 1226, 10.1210/en.2004-0735 · DOI · Paper page
  14. Schwartz, 2006, Thiazolidinedione use and bone loss in older diabetic adults., J Clin Endocrinol Metab, 91, 3349, 10.1210/jc.2005-2226 · DOI · Paper page
  15. Strotmeyer, 2005, Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study., Arch Intern Med, 165, 1612, 10.1001/archinte.165.14.1612 · DOI · Paper page
  16. Liefde, 2005, Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study., Osteoporos Int, 16, 1713, 10.1007/s00198-005-1909-1 · DOI · Paper page
  17. Nicodemus, 2001, Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women., Diabetes Care, 24, 1192, 10.2337/diacare.24.7.1192 · DOI · Paper page
  18. Vestergaard, 2005, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk., Diabetologia, 48, 1292, 10.1007/s00125-005-1786-3 · DOI · Paper page
  19. Taylor, 2004, Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures., J Am Geriatr Soc, 52, 1479, 10.1111/j.1532-5415.2004.52410.x · DOI · Paper page
  20. Strotmeyer, 2004, Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study., J Bone Miner Res, 19, 1084, 10.1359/JBMR.040311 · DOI · Paper page
  21. Bonds, 2006, Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study., J Clin Endocrinol Metab, 91, 3404, 10.1210/jc.2006-0614 · DOI · Paper page
  22. Reid, 2004, Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone., Bone, 35, 224, 10.1016/j.bone.2004.03.023 · DOI
  23. Reid, 2005, Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial., J Clin Endocrinol Metab, 90, 5212, 10.1210/jc.2005-0573 · DOI
  24. Truxillo C, Maximum likelihood parameter estimation with incomplete data. SAS Users Group International Conference, Philadelphia, PA, 2005 (http://www2.sas.com/proceedings/sugi30/111-30.pdf)
  25. Ton, 2005, Effects of low-dose prednisone on bone metabolism., J Bone Miner Res, 20, 464, 10.1359/JBMR.041125 · DOI · Paper page
  26. Reid, 1997, Glucocorticoid osteoporosis—mechanisms and management., Eur J Endocrinol, 137, 209, 10.1530/eje.0.1370209 · DOI · Paper page
  27. Staels, 2005, Therapeutic roles of peroxisome proliferator-activated receptor agonists., Diabetes, 54, 2460, 10.2337/diabetes.54.8.2460 · DOI · Paper page
  28. Ehrmann, 2005, Polycystic ovary syndrome., N Engl J Med, 352, 1223, 10.1056/NEJMra041536 · DOI · Paper page
  29. 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial., Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 · DOI · Paper page
  30. Rzonca, 2004, Bone is a target for the antidiabetic compound rosiglitazone., Endocrinology, 145, 401, 10.1210/en.2003-0746 · DOI · Paper page
  31. Lecka-Czernik, 2002, Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation., Endocrinology, 143, 2376, 10.1210/endo.143.6.8834 · DOI · Paper page
  32. Jennermann, 1995, Effects of thiazolidinediones on bone turnover in the rat, J Bone Miner Res, 10, S241
  33. Syversen, 2003, PPAR-α agonists increase bone mineral density in female rats, J Bone Miner Res, 18, S42
  34. Li, 2006, Surface-specific effects of a PPAR-γ agonist, darglitazone, on bone in mice., Bone, 39, 796, 10.1016/j.bone.2006.04.008 · DOI
  35. Lazarenko, 2006, Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat., Bone, 38, 74, 10.1016/j.bone.2005.07.008 · DOI
  36. Okazaki, 1999, Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus., Endocr J, 46, 795, 10.1507/endocrj.46.795 · DOI
  37. Watanabe, 2003, Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients., J Bone Miner Metab, 21, 166, 10.1007/s007740300026 · DOI
  38. Cornish, 2002, Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo., J Endocrinol, 175, 405, 10.1677/joe.0.1750405 · DOI · Paper page
  39. Cornish, 1996, Insulin increases histomorphometric indices of bone formation in vivo., Calcif Tissue Int, 59, 492, 10.1007/BF00369216 · DOI
  40. Justesen, 2004, Mice deficient in 11β-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation., Endocrinology, 145, 1916, 10.1210/en.2003-1427 · DOI
  41. Okazaki, 1997, Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover., J Clin Endocrinol Metab, 82, 2915

Cited by

See all 401

Metadata

Authors
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2007-04-01
Volume
92
Issue
4
Pages
1305-1310
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2006-2646
OpenAlex
W1976942305
Cited by
401
References
3
FWCI
49.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.1210/jc.2006-2646
The paper
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R. (2007). The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2006-2646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.